Your browser doesn't support javascript.
loading
Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma.
Franco, Abigail I; Eastwick, Gary; Farah, Ramsay; Heyboer, Marvin; Lee, Mijung; Aridgides, Paul.
Affiliation
  • Franco AI; St. Joseph's Hospital Health Center, 301 Prospect Avenue, Syracuse, NY 13203, USA.
  • Eastwick G; Upstate University Hospital, 750 E. Adams Street, Syracuse, NY 13210, USA.
  • Farah R; Upstate University Hospital, 750 E. Adams Street, Syracuse, NY 13210, USA.
  • Heyboer M; Upstate University Hospital, 750 E. Adams Street, Syracuse, NY 13210, USA.
  • Lee M; Upstate University Hospital, 750 E. Adams Street, Syracuse, NY 13210, USA.
  • Aridgides P; Upstate University Hospital, 750 E. Adams Street, Syracuse, NY 13210, USA.
Case Rep Dermatol Med ; 2018: 2354146, 2018.
Article in En | MEDLINE | ID: mdl-29682362
ABSTRACT
We present a case report of a male with multifocal and extensive basal cell carcinoma. Due to extremely large size and deep tumor infiltration, he was not a surgical candidate. Combined modality treatment of fractionated radiation with concurrent vismodegib was chosen. Concurrent treatment was previously reported in the palliative and recurrent setting. This is the first case of concurrent vismodegib and radiation therapy for upfront definitive management. The patient experienced complete response in all treated lesions.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Case Rep Dermatol Med Year: 2018 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Case Rep Dermatol Med Year: 2018 Document type: Article Affiliation country: United States